Abstract
No public abstract is available from the verified source records.
Jan L. Shifren
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Managing menopausal symptoms and associated clinical issues in breast cancer survivors
10.1210/jc.2017-01138 · 2017
The 2022 hormone therapy position statement of The North American Menopause Society
10.1097/gme.0000000000002028 · 2022
Use of transdermal testosterone to treat menopausal symptoms in women with a history of breast cancer: a small, retrospective, open-label study
2026
Global Consensus Position Statement on the Use of Testosterone Therapy for Women
10.1210/jc.2019-01603 · 2019
International Society for the Study of Women’s Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women
10.1016/j.jsxm.2020.10.009 · 2021
The 2023 nonhormone therapy position statement of The North American Menopause Society
10.1097/gme.0000000000002200 · 2023
Not just sex: other roles for testosterone in women
10.1080/13697137.2024.2445301 · 2025
Efficacy and safety of fezolinetant in moderate-to-severe vasomotor symptoms associated with menopause: a phase 3 RCT
10.1210/clinem/dgad058 · 2023
Elinzanetant for the treatment of vasomotor symptoms associated with menopause: OASIS 1 and 2 randomized clinical trials
10.1001/jama.2024.14618 · 2024
Elinzanetant for vasomotor symptoms from endocrine therapy for breast cancer
10.1056/nejmoa2415566 · 2025
Libigel (testosterone gel) does not differentiate from placebo therapy in the treatment of hypoactive sexual desire in postmenopausal women (Abstract)
2012
Testosterone for low libido in postmenopausal women not taking estrogen
10.1056/nejmoa0707302 · 2008
No additional external references are available.